Articles
Study Results

Why Does Retatrutide Increase Heart Rate? What the Trials Show

Retatrutide raised heart rate in its trials, more at higher doses, with a peak and then a decline in the higher-dose groups during treatment. The published numbers, the possible reasons, and what is still unknown.

Written By
retaweightloss.com
Updated on
11 Nov 2026
Time to read
5 min read
Category
Study Results
Why Does Retatrutide Increase Heart Rate?

Why Does Retatrutide Increase Heart Rate? What the Trials Show

Retatrutide raised heart rate in its trials, more at higher doses, with a peak and then a decline in the higher-dose groups during treatment. The published numbers, the possible reasons, and what is still unknown.

By
RetaWeightLoss.com
Created on:
12 Jul 2026
Updated on:
11 Nov 2026
Share this post

Does Retatrutide Increase Heart Rate? The Short Answer

Yes. Retatrutide raised heart rate in its clinical trials, and the increase was larger at higher doses. It is one of several side effects seen in the trials. In the Phase 2 trial, average 24-hour heart rate in the highest-dose group (12 mg) was 9.2 beats per minute (bpm) above its starting level at week 24, compared with 0.8 bpm on placebo. The increase then eased while treatment continued. The larger Phase 3 TRIUMPH-1 trial showed the same pattern: pulse rate on 12 mg peaked at about 8 bpm above its starting level at week 20 and was 2.6 bpm above it at week 80 (model-based estimate), against a fall of 0.3 bpm on placebo, according to the paper's supplementary appendix.

Why it happens has not been established. The Phase 2 researchers note that glucagon and GLP-1, two of the three hormones retatrutide mimics, "can exert positive chronotropic and inotropic effects on the heart," meaning they can make the heart beat faster and more forcefully. The trials were not designed to show which of retatrutide's three receptor actions is responsible.

How Much Does Retatrutide Raise Heart Rate?

The most detailed published figures come from the 48-week Phase 2 trial (Jastreboff et al., New England Journal of Medicine, 2023), which randomized 338 adults with obesity or overweight and without diabetes to placebo or one of six retatrutide regimens. Heart rate was measured with 24-hour ambulatory monitoring, which records it around the clock rather than in a single clinic reading. Some regimens started at a lower dose (2 mg) and others at a higher one (4 mg) before stepping up.

Group Change at week 24 (bpm) Change at week 36 (bpm)
Placebo +0.8 +0.9
Retatrutide 1 mg +0.7 +2.7
Retatrutide 4 mg (started at 2 mg) +4.2 +3.6
Retatrutide 4 mg (started at 4 mg) +2.2 +2.6
Retatrutide 8 mg (started at 2 mg) +5.7 +5.6
Retatrutide 8 mg (started at 4 mg) +6.0 +3.9
Retatrutide 12 mg (started at 2 mg) +9.2 +6.7


Three points stand out. The increase broadly rose with dose: at week 24 the 1 mg group's change (0.7 bpm) was similar to placebo's (0.8 bpm), while the 12 mg group had the largest increase. The increase was smaller at week 36 than at week 24 in most retatrutide groups, including 12 mg (6.7 vs 9.2 bpm). And these are group averages, so individual people may have had larger or smaller changes.

The paper summarizes the pattern this way: heart rate "increased with retatrutide treatment in a dose-dependent manner, peaking at 24 weeks, followed by a decline at 36 and 48 weeks."

What the Phase 3 TRIUMPH-1 Trial Shows

TRIUMPH-1, published in the New England Journal of Medicine on September 29, 2026, compared retatrutide 4 mg, 9 mg and 12 mg with placebo for 80 weeks in 2,339 adults with obesity or overweight and without diabetes. Its main text reports: "The mean pulse rate increased with retatrutide, peaking at 20 weeks in the 9-mg and 12-mg groups and decreased thereafter."

The size of the increase is given in the paper's supplementary appendix. Its table reports pulse rate at the start and at week 80, and its chart shows the change over time:

TRIUMPH-1 group Pulse at start (bpm) Pulse at week 80 (bpm) Change at week 80 (bpm)
Placebo 72.9 72.3 −0.3
Retatrutide 4 mg 72.6 74.1 +1.5
Retatrutide 9 mg 72.8 75.3 +2.7
Retatrutide 12 mg 72.2 75.1 +2.6


All figures in this table are model-based estimates from the appendix, so the change column does not exactly equal the difference between the two pulse columns. The size of the peak is shown only in the chart, which plots average observed values during treatment: about 8 bpm above the starting level on 12 mg and about 7 bpm on 9 mg at week 20, and about 4 bpm on 4 mg between weeks 8 and 20, all values read from the chart. All groups started at a normal average of about 72 to 73 bpm. TRIUMPH-1 reports these as pulse rate, and neither the paper nor the appendix describes how it was measured; the Phase 2 figures came from 24-hour monitoring, so the two trials' numbers are not directly comparable. The company's June 6, 2026, press release on the TRIUMPH-1 results does not report heart rate. Blood pressure, which fell on retatrutide, is covered in retatrutide and blood pressure.

Why Does Retatrutide Increase Heart Rate?

Retatrutide activates three hormone receptors: GIP, GLP-1 and glucagon. Medicines that act only on the GLP-1 receptor, such as semaglutide, or on the GIP and GLP-1 receptors, such as tirzepatide, also raise heart rate, according to their US prescribing information. So a rise in heart rate is not unique to retatrutide or to its glucagon component.

The Phase 2 authors point to both hormones: "Glucagon and GLP-1 can exert positive chronotropic and inotropic effects on the heart." They also note that the increases they saw were "similar to those reported for GLP-1 receptor agonists."

Whether glucagon receptor activation adds to the effect has not been shown. The retatrutide trials described here compared it with placebo, not with semaglutide or tirzepatide, so they cannot separate the contribution of each receptor. Statements that glucagon is "the cause" go beyond what the published data show.

Retatrutide Heart Rate vs Semaglutide and Tirzepatide

Comparing heart rate across separate trials is unreliable: the figures were measured in different ways, at different times and in different people. With that caveat, this is how each medicine's effect is reported.

Medicine Source What is reported
Retatrutide (investigational) Phase 2 trial, NEJM 2023 Change from starting level on 24-hour monitoring: up to +9.2 bpm (12 mg) at week 24 vs +0.8 bpm on placebo; +6.7 vs +0.9 at week 36
Retatrutide (investigational) TRIUMPH-1, NEJM 2026 Change in pulse rate from starting level: about +8 bpm at the week-20 peak on 12 mg (read from the appendix chart); +2.6 bpm on 12 mg vs −0.3 bpm on placebo at week 80
Semaglutide (Wegovy) US prescribing information Mean resting heart rate 1 to 4 bpm higher than placebo in adult weight-management trials
Tirzepatide (Zepbound) US prescribing information Mean heart rate 1 to 3 bpm higher, compared with no increase on placebo


The approved-drug figures are differences from placebo. The retatrutide Phase 2 figures are each group's change from its own starting level, measured over 24 hours, reported alongside the placebo group's change. Subtracting placebo from the 12 mg result at week 24 gives about 8 bpm, but that is a calculation from two group averages, not a figure the paper reports, and it comes from a different kind of measurement. The same calculation for TRIUMPH-1 at week 80 gives about 3 bpm, within the range on the approved drugs' labels, but again from separate trials. Only a trial testing the medicines against each other under the same conditions could show which raises heart rate more. How the three drugs compare more broadly is covered in retatrutide vs tirzepatide vs semaglutide.

The US label for semaglutide for weight management contains a "Heart Rate Increase" warning (section 5.9). The US label for tirzepatide for weight management reports the increase under adverse reactions and has no separate warning section on heart rate.

Heart Rhythm Problems in the Trials

Heart rate (how fast the heart beats) is different from heart rhythm (whether it beats regularly). The trials reported rhythm problems separately.

In Phase 2, cardiac arrhythmias were tracked as an adverse event of special interest. They were reported in 11% (7 of 62) of the 12 mg group and 3% (2 of 70) of the placebo group; in the other retatrutide groups, which had 33 to 69 people each, rates ranged from 0% to 14%. The paper says the reported arrhythmias were mild to moderate, except one severe event (prolonged QT syndrome) in a participant treated with ondansetron, an anti-nausea medicine.

In TRIUMPH-1, which was much larger, severe or serious arrhythmia or cardiac conduction disorder occurred in 0.2% of the 4 mg group, 0.7% of the 9 mg group and 0.9% of the 12 mg group, and in 0.9% of the placebo group.

Does the Heart Rate Increase Go Away?

During treatment, it partly eased in both trials. In Phase 2, the 12 mg group's increase fell from 9.2 bpm at week 24 to 6.7 bpm at week 36, still above placebo (0.9 bpm). In TRIUMPH-1, pulse rate on 12 mg went from about 8 bpm above the starting level at week 20 to 2.6 bpm above it at week 80, and on 9 mg from about 7 to 2.7 bpm, while it changed little on placebo.

What happens after stopping is not described in these publications. We found no heart rate data after treatment ended in the Phase 2 paper or in the TRIUMPH-1 paper and its appendix, although both trials included four weeks of follow-up after treatment. Claims that the increase fully reverses within a set number of weeks are not supported by these papers. Some people also link a faster heartbeat with feeling hot; what is known about that is covered in retatrutide and body temperature.

What Is Still Unknown

  • The cause. Whether the glucagon component adds to the heart rate effect seen with GLP-1-based medicines has not been tested directly.
  • Heart rate after stopping. Not described in the publications reviewed here.
  • Long-term heart outcomes. TRIUMPH-Outcomes, a Lilly trial in people with obesity and atherosclerotic cardiovascular disease and/or chronic kidney disease, is evaluating cardiovascular and kidney outcomes. It has not reported results (see retatrutide long-term safety).

Retatrutide is an investigational medicine. It has not been approved by the FDA or any other regulator, and its full safety profile, including its effects on the heart, is still being studied.

Sources

  • Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023, and supplementary appendix (Tables S6 and S8).
  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026. DOI: 10.1056/NEJMoa2604169. Updated October 22, 2026; Supplementary Appendix, Table S12 and Figure S22. (TRIUMPH-1)
  • Eli Lilly. Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications. June 6, 2026.
  • Eli Lilly. What to know about retatrutide.
  • Novo Nordisk. Wegovy (semaglutide) US prescribing information, section 5.9. Revised June 2026.
  • Eli Lilly. US prescribing information for tirzepatide for weight reduction, section 6.1. Revised August 2026.
  • Lilly Trials. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults (TRIUMPH-Outcomes). NCT06383390, trial listing.

Medical Disclaimer: This article is for informational purposes only and is not medical advice. Retatrutide is investigational and is not approved by the FDA for any use. It is not available by prescription, and Lilly says no one can legally sell it for human use. Nothing here is a recommendation to use, seek out or avoid any medication.

Frequently asked questions

Why does retatrutide increase heart rate?

The exact reason has not been established. Retatrutide acts on GIP, GLP-1 and glucagon receptors, and the Phase 2 researchers note that glucagon and GLP-1 can make the heart beat faster and more forcefully. Medicines acting on the GLP-1 receptor without glucagon also raise heart rate, and the trials were not designed to show how much each receptor contributes.

How much does retatrutide raise heart rate?

In the Phase 2 trial, 24-hour heart rate rose by 0.7 to 9.2 beats per minute at week 24 depending on dose, with the largest increase on 12 mg, compared with 0.8 on placebo. At week 36 the 12 mg increase was 6.7, compared with 0.9 on placebo. In the Phase 3 TRIUMPH-1 trial, pulse rate on 12 mg was 2.6 beats per minute above its starting level at week 80, against a fall of 0.3 on placebo.

Does the heart rate increase go away?

It partly eased during treatment. In Phase 2 the researchers report that the increase peaked at week 24 and declined afterwards. In TRIUMPH-1, pulse rate on 12 mg peaked at about 8 beats per minute above its starting level at week 20 and was 2.6 above it at week 80. We found no heart rate data after treatment stopped in either trial's publications.

Does retatrutide raise heart rate more than semaglutide or tirzepatide?

That has not been shown directly. Retatrutide was compared with semaglutide 2 mg in TRANSCEND-T2D-2, a Phase 3 trial in type 2 diabetes, but the topline results announced in October 2026 do not report heart rate. The US labels of semaglutide and tirzepatide report mean increases of 1 to 4 and 1 to 3 beats per minute over placebo, while retatrutide’s figures come from separate trials measured differently, so they cannot be compared reliably.

Newsletter

Stay Updated on New Articles & Research

Get notified when we publish new articles, research, and insights on obesity and weight loss.
You're subscribed!
You'll get new coverage as it's published.
Oops! Something went wrong while submitting the form.